These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
376 related articles for article (PubMed ID: 22315424)
1. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Volinia S; Galasso M; Sana ME; Wise TF; Palatini J; Huebner K; Croce CM Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3024-9. PubMed ID: 22315424 [TBL] [Abstract][Full Text] [Related]
3. Expression of microRNA and their gene targets are dysregulated in preinvasive breast cancer. Hannafon BN; Sebastiani P; de las Morenas A; Lu J; Rosenberg CL Breast Cancer Res; 2011 Mar; 13(2):R24. PubMed ID: 21375733 [TBL] [Abstract][Full Text] [Related]
4. Role of deregulated microRNAs in breast cancer progression using FFPE tissue. Chen L; Li Y; Fu Y; Peng J; Mo MH; Stamatakos M; Teal CB; Brem RF; Stojadinovic A; Grinkemeyer M; McCaffrey TA; Man YG; Fu SW PLoS One; 2013; 8(1):e54213. PubMed ID: 23372687 [TBL] [Abstract][Full Text] [Related]
5. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study. Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365 [TBL] [Abstract][Full Text] [Related]
6. The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer. Krstic M; Macmillan CD; Leong HS; Clifford AG; Souter LH; Dales DW; Postenka CO; Chambers AF; Tuck AB BMC Cancer; 2016 Aug; 16(1):671. PubMed ID: 27553211 [TBL] [Abstract][Full Text] [Related]
7. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525 [TBL] [Abstract][Full Text] [Related]
8. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a. Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225 [TBL] [Abstract][Full Text] [Related]
9. Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer. Lesurf R; Aure MR; Mørk HH; Vitelli V; ; Lundgren S; Børresen-Dale AL; Kristensen V; Wärnberg F; Hallett M; Sørlie T Cell Rep; 2016 Jul; 16(4):1166-1179. PubMed ID: 27396337 [TBL] [Abstract][Full Text] [Related]
10. Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Abba MC; Drake JA; Hawkins KA; Hu Y; Sun H; Notcovich C; Gaddis S; Sahin A; Baggerly K; Aldaz CM Breast Cancer Res; 2004; 6(5):R499-513. PubMed ID: 15318932 [TBL] [Abstract][Full Text] [Related]
12. Breaking down barriers: the importance of the stromal microenvironment in acquiring invasiveness in young women's breast cancer. Schedin P; Borges V Breast Cancer Res; 2009; 11(2):102. PubMed ID: 19344495 [TBL] [Abstract][Full Text] [Related]
13. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Volinia S; Croce CM Proc Natl Acad Sci U S A; 2013 Apr; 110(18):7413-7. PubMed ID: 23589849 [TBL] [Abstract][Full Text] [Related]
14. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB Clin Cancer Res; 2007 Jan; 13(2 Pt 1):467-74. PubMed ID: 17255267 [TBL] [Abstract][Full Text] [Related]
15. Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer. Citron F; Segatto I; Vinciguerra GLR; Musco L; Russo F; Mungo G; D'Andrea S; Mattevi MC; Perin T; Schiappacassi M; Massarut S; Marchini C; Amici A; Vecchione A; Baldassarre G; Belletti B Cancer Res; 2020 Mar; 80(5):1064-1077. PubMed ID: 31862778 [TBL] [Abstract][Full Text] [Related]
16. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Kristensen VN; Vaske CJ; Ursini-Siegel J; Van Loo P; Nordgard SH; Sachidanandam R; Sørlie T; Wärnberg F; Haakensen VD; Helland Å; Naume B; Perou CM; Haussler D; Troyanskaya OG; Børresen-Dale AL Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2802-7. PubMed ID: 21908711 [TBL] [Abstract][Full Text] [Related]
17. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status. Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722 [TBL] [Abstract][Full Text] [Related]
18. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854 [TBL] [Abstract][Full Text] [Related]
19. Identification of aberrant gene expression during breast ductal carcinoma Song G; He L; Yang X; Yang Y; Cai X; Liu K; Feng G J Int Med Res; 2020 Jan; 48(1):300060518815364. PubMed ID: 30712460 [TBL] [Abstract][Full Text] [Related]
20. The microRNA-205-5p is correlated to metastatic potential of 21T series: A breast cancer progression model. Stankevicins L; Barat A; Dessen P; Vassetzky Y; de Moura Gallo CV PLoS One; 2017; 12(3):e0173756. PubMed ID: 28346474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]